Earendil Labs, a biotechnology company leveraging artificial intelligence to advance next-generation biologics, has announced it has raised $787 million in a major financing round. 

 

Leading global investors—including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and the Biotech Development Fund (created by Hillhouse and Pfizer)—participated alongside other technology and healthcare-focused backers.

 

The infusion of capital will accelerate Earendil Labs’ AI-driven R&D platform, expand its interdisciplinary teams, and push forward its growing pipeline of antibody and biologics programs aimed at delivering first-in-class and best-in-class therapies for patients with serious diseases.

 

"AI is at the core of everything we do — not as a research tool, but as a production engine for real therapeutic programs," said Jian Peng, Founder and CEO of Earendil Labs. "This financing allows us to operate at a fundamentally different scale, advancing multiple programs toward the clinic while building an R&D organization designed for long-term impact."

 

Earendil Labs integrates artificial intelligence across the full lifecycle of biologics R&D, enabling the systematic generation and progression of differentiated therapeutic programs. Its AI-native platform has produced more than 40 programs, including HXN-1001, a half-life extended anti-TL1A antibody ready for Phase 2 clinical development, with multiple IND submissions planned for 2026 and 2027.

 

"Our focus is ultimately on patients suffering from diseases that still lack effective treatment options," said Zhenping Zhu, Co-Founder, President and Co-CEO of Earendil Labs. "This funding greatly strengthens our ability to translate AI-enabled innovation into potentially transformative medicines and provides opportunities to partner with global leaders to accelerate our research and development programs worldwide."

 

The platform’s productivity and R&D execution are reinforced by strategic collaborations with Sanofi. In 2025, Earendil Labs signed a worldwide exclusive license agreement with Sanofi for next-generation bispecific antibodies targeting autoimmune and inflammatory bowel diseases.

 

"Earendil Labs stands out for its ability to translate AI innovation into real, scalable R&D execution," said Zavain Dar, Founding Managing Partner at Dimension Capital. "The team has shown that AI can consistently generate high-quality biologics programs and advance them toward the clinic. We are excited to support Earendil Labs as it builds a new paradigm for biologics discovery and development."